Protagenic Therapeutics (OTCMKTS:PTIX) and PFSweb (NASDAQ:PFSW) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.
This table compares Protagenic Therapeutics and PFSweb’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
57.7% of PFSweb shares are owned by institutional investors. 51.1% of Protagenic Therapeutics shares are owned by company insiders. Comparatively, 6.5% of PFSweb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Protagenic Therapeutics and PFSweb, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
PFSweb has a consensus price target of $10.33, indicating a potential upside of 157.05%. Given PFSweb’s higher probable upside, analysts plainly believe PFSweb is more favorable than Protagenic Therapeutics.
Risk & Volatility
Protagenic Therapeutics has a beta of -7.94, suggesting that its stock price is 894% less volatile than the S&P 500. Comparatively, PFSweb has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
Earnings & Valuation
This table compares Protagenic Therapeutics and PFSweb’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Protagenic Therapeutics||N/A||N/A||-$2.56 million||N/A||N/A|
|PFSweb||$326.16 million||0.24||$1.23 million||N/A||N/A|
PFSweb has higher revenue and earnings than Protagenic Therapeutics.
PFSweb beats Protagenic Therapeutics on 9 of the 10 factors compared between the two stocks.
About Protagenic Therapeutics
Protagenic Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.
PFSweb, Inc. provides omni-channel commerce solutions in the United States, Europe, Canada, and India. It operates through two segments, LiveArea Professional Services and PFS Operations. The company offers strategic commerce consulting services, including commerce strategy, omni-channel consulting, digital opportunity audit, organizational/operational readiness, and platform evaluation/selection services; and design and digital marketing services, such as design, user experience, interactive development, search engine optimization and paid search, affiliate marketing, conversion optimization, storefront management, email marketing, and digital analytics. It also provides technology services comprising commerce development, managed, quality assurance, and training services; and order to cash service, such as technology collaboration, information management services, payments, business-to-business financial management, and direct-to-consumer financial management. In addition, the company offers fulfillment services, including distribution facilities and infrastructure, facility operations and management, pop-up distribution centers, and kitting and assembly services; and customer care services comprising customer service application, customer assistance, quality monitoring, and customer self-help. It serves clients in various industries, such as fashion apparel and accessories, fragrance and beauty products, consumer packaged goods, home furnishings and housewares, coins and collectibles, and technology products. The company was founded in 1999 and is headquartered in Allen, Texas.
Receive News & Ratings for Protagenic Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Protagenic Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.